Wilmington, Delaware--(Newsfile Corp. - April 17, 2023) - Rigrodsky Law, P.A. is investigating Satsuma Pharmaceuticals, Inc. ("Satsuma") STSA regarding possible breaches of fiduciary duties and other violations of law related to Satsuma's agreement to be acquired by Shin Nippon Biomedical Laboratories, Ltd. Under the terms of the agreement, Satsuma shareholders will receive $0.91 per share in cash.
To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-satsuma-pharmaceuticals-inc.
To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.
Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.
Attorney advertising. Prior results do not guarantee a similar outcome.
Contact:
Rigrodsky Law, P.A.
Seth D. Rigrodsky, Esq.
Gina M. Serra, Esq.
Call or Text: (302) 295-5310
Email: info@rl-legal.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/162735
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
